Verastem Enters Biomarker Agreement with LabCorp for Cancer Stem Cell Agent Companion Diagnostic
:The identification of patients most likely to benefit from targeted therapy is critical to accelerating the drug development and approval process,” said Henri Termeer, Verastem Lead Director.
Clinical assay validation is an integral component to all companion diagnostics entering an FDA approval process.
Pioneering research by Robert Weinberg, Ph.D., Verastem cofounder and chair of the Scientific Advisory Board, and others have demonstrated that FAK signaling plays a central role in the tumor-initiating capability of cancer stem cells and ultimate disease progression. VS-6063 is designed to target and kill cancer stem cells by inhibiting FAK signaling.
Mesothelioma tumors lacking the tumor suppressor Merlin appear to be particularly sensitive to FAK inhibitors. As shown recently at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, sensitivity due to lack of Merlin is evident in both research models and early clinical proof-of-concept.
SANTA CRUZ BIOTECHNOLOGY
|Solubility:||Soluble to 100 mM in Water and to 75 mM in DMSO|
|Melting Point:||>300 °C lit.|
2. Golubovskaya, V.M., et al. 2008. J. Med. Chem. 51: 7405-7416. PMID: 18989950
3. Hochwald, S.N., et al. 2009. Cell Cycle. 8: 2435-2443. PMID: 19571674
4. Beierle, E.A., et al. 2010. Cell Cycle. 9: 1005-1015. PMID: 20160475
3 total citations